Distinct Roles of Beta-Cell Mass and Function During Diabetes Onset and Remission

Dear Colleagues,

Both type 1 and type 2 diabetes are characterized by a deficit of beta cell mass. Although type 2 diabetes is characterized by insulin resistance and beta cell dysfunction, recent studies have suggested that diabetes never develops unless beta cell function fails to compensate insulin resistance. Also, while bariatric surgery is now expected to be one of the most potent therapy to achieve remission of type 2 diabetes, a critical role of beta cell function on remission rate after the surgery has been suggested. Nonetheless, precise mechanisms of beta cell dysfunction in diabetes remains fully elucidated, and better understanding of distinct as well as simultaneous roles of beta cell mass and function during diabetes onset and remission is crucial to develop novel and effective strategies for prevention and cure of diabetes.

In this special issue, authors are welcome to submit any types of article such as original article, review article, perspective and opinion, regarding beta cell mass and/or function during diabetes onset and remission. Topics include, but are not limited to,

• both basic and clinical studies
• etiology
• islet biology
• beta and alpha cell function
• incretin and other hormones
• regenerative medicine
• biomarkers
• genetic studies
• bariatric surgery
• microbes
• lifestyle and pharmacological interventions

Prof. Yoshifumi Saisho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Beta cell mass during onset and/or remission of diabetes
• Beta cell function during onset and/or remission of diabetes
• Type 1 diabetes
• Type 2 diabetes
• Gestational diabetes
• Prevention strategies of diabetes
• Lifestyle and pharmacological interventions
• Bariatric surgery